Non-Monograph Drugs Interim Marketing Preservation Urged By CHPA

FDA's proposed rule on "material time, material extent" criteria for inclusion of drug conditions in the OTC review would "effectively terminate" the monograph process, CHPA maintains in a March 22 letter to the agency.